The Latest Breaking News from FDA

Overdoses may have arisen from patients with poor knowledge of drug measurements and medical equipment, such as syringes, according to public health officials

Down 84% from all-time highs, Compass Pathways is a beaten-down biotech stock that trades at a massive discount to consensus price target estimates in 2024.

Scientists hope a new blood test for colorectal cancer could improve screening rates.

With the FDA's approval, it is very likely that private insurance companies and Medicare will cover the cost of the blood test, making it more accessible for patients.

A rise in counterfeit versions of sought-after weight loss drug has led to a series of hospitalisations.

FDA approves Guardant's Shield test for colon cancer screening in adults aged 45 and above, providing a convenient and accessible method for early detection.

The drugmaker Teva Pharmaceuticals made history in June by launching the first-ever generic version of a GLP-1 diabetes drug.

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

The history of the Nutrition Facts label shows us how we got to this somewhat confusing, but helpful, set of facts printed on our food stuffs.

Wandercraft, the French company that developed the exoskeleton suit, recently got FDA approval to use them for stroke rehab in the U.S.

With robots making waves across industries from healthcare to manufacturing, now might be the perfect time to invest in leading players such as Intuitive Surgical (ISRG), Fanuc Corp. (FANUY), and iRobot Corp. (IRBT) to garner solid returns. Read on….